- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
- Willems E, Dedobbeleer M, Digregorio M, et al. The functional diversity of Aurora kinases: a comprehensive review. Cell Div. 2018;13:7.
- Tang A, Gao K, Chu L, et al. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8:23937–23954.
- Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786:60–72.
- Kufer TA, Silljé HH, Körner R, et al. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol. 2002;158:617–623.
- Ma HT, Poon RYC. Aurora kinases and DNA damage response. Mutat Res. 2020;821:111716.
- D’Assoro AB, Haddad T, Aurora-A GE. Kinase as a Promising Therapeutic Target in Cancer. Front Oncol. 2015;5:295.
- Borisa AC, Bhatt HG. A comprehensive review on Aurora kinase: small molecule inhibitors and clinical trial studies. Eur J Med Chem. 2017;140:1–19.
- Gully CP, Velazquez-Torres G, Shin JH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA. 2012;109:E1513–1522.
- Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4:927–936.
- Fu J, Bian M, Jiang Q, et al. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007;5:1–10.
- Quartuccio S, Schindler K. Functions of Aurora kinase C in meiosis and cancer. Front Cell Dev Biol. 2015;3:50.
- Carry JC, Clerc F, Minoux H, et al. SAR156497, an exquisitely selective inhibitor of aurora kinases. J Med Chem. 2015;58:362–375.
- Qi B, Zhong L, He J, et al. Discovery of inhibitors of Aurora/PLK targets as anticancer agents. J Med Chem. 2019;62:7697–7707.
- Kim WH, Jeong P, Kim SW, et al. A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity. Bioorg Med Chem. 2019;27:2923–2934.
- Lakkaniga NR, Zhang L, Belachew B, et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. Eur J Med Chem. 2020;203:112589.
- Coumar MS, Cheung CH, Chang JY, et al. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat. 2009;19:321–356.
- Cheung CH, Coumar MS, Chang JY, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009–2010). Expert Opin Ther Pat. 2011;21:857–884.
- Cheung CH, Sarvagalla S, Lee JY, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013). Expert Opin Ther Pat. 2014;24:1021–1038.
- Ding L, Gu H, Gao X, et al. Aurora kinase a regulates m1 macrophage polarization and plays a role in experimental autoimmune encephalomyelitis. Inflammation. 2015;38:800–811.
- Liu J, Qin CY. VX-680 induces p53-mediated apoptosis in human cholangiocarcinoma cells. Anticancer Drugs. 2018;29:1004–1010.
- Jin X, Mo Q, Zhang Y, et al. The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer. Cancer Biol Ther. 2016;17:566–576.
- Seymour JF, Kim DW, Rubin E, et al. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e238.
- Tuccilli C, Baldini E, Prinzi N, et al. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line. Endocrine. 2016;52:287–295.
- Ghanizadeh-Vesali S, Zekri A, Zaker F, et al. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia. Ann Hematol. 2016;95:1031–1042.
- Zekri A, Ghaffari SH, Ghanizadeh-Vesali S, et al. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumor Biol. 2015;36:623–632.
- Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Mol Cancer Ther. 2016;15:2314–2322.
- Zekri A, Ghaffari SH, Yaghmaie M, et al. Inhibitor of Aurora kinase B induces differentially cell death and polyploidy via DNA damage response pathways in neurological malignancy: shedding new light on the challenge of resistance to AZD1152-HQPA. Mol Neurobiol. 2016;53:1808–1823.
- Matsunaga H, Tanaka S, Aihara A, et al. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma. Ann Surg Oncol. 2015;22:3079–3086.
- Li JJ, Hong MJ, Chow JPH, et al. Co-inhibition of polo-like kinase 1 and aurora kinases promotes mitotic catastrophe. Oncotarget 2015;6:9327–9340.
- Wang S, Hwang EE, Guha R, et al. High-throughput chemical screening identifies focal adhesion kinase and Aurora kinase B inhibition as a synergistic treatment combination in Ewing sarcoma. Clin Cancer Res. 2019;25:4552–4566.
- Collins GP, Eyre TA, Linton KM, et al. A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. Br J Haematol. 2015;170:886–890.
- Gavriilidis P, Poutahidis T, Giakoustidis A, et al. Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib. J Cancer. 2018;9:914–922.
- Liu J, Hong J, Ahn KS, et al. ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines. Leuk Lymphoma. 2019;60:2532–2540.
- Schöffski P, Besse B, Gauler T, et al. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumor, multi-institutional phase II study. Ann Oncol. 2015;26:598–607.
- Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;100:898–904.
- Zhou X, Pusalkar S, Chowdhury SK, et al. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [(14)C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. Invest New Drugs. 2019;37:666–673.
- Venkatakrishnan K, Kim TM, Lin CC, et al. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Invest New Drugs. 2015;33:942–953.
- Falchook G, Kurzrock R, Gouw L, et al. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014;32:1181–1187.
- Beltran H, Oromendia C, Danila DC, et al. A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res. 2019;25:43–51.
- Barr PM, Li H, Spier C, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-Cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33:2399–2404.
- Dickson MA, Mahoney MR, Tap WD, et al. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol. 2016;27:1855–1860.
- Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32:44–50.
- Melichar B, Adenis A, Lockhart AC, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.
- Necchi A, Lo Vullo S, Mariani L, et al. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Invest New Drugs. 2016;34:236–242.
- O’Connor OA, Özcan M, Jacobsen ED, et al. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-Cell lymphoma. J Clin Oncol. 2019;37:613–623.
- DuBois SG, Marachelian A, Fox E, et al. Phase I study of the Aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial. J Clin Oncol. 2016;34:1368–1375.
- Shah HA, Fischer JH, Venepalli NK, et al. Phase I study of Aurora A kinase inhibitor alisertib (MLN8237) in combination with selective VEGFR inhibitor Pazopanib for therapy of advanced solid tumors. Am J Clin Oncol. 2019;42:413–420.
- Haddad TC, D’Assoro A, Suman V, et al. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Res Treat. 2018;168:639–647.
- Goff LW, Azad NS, Stein S, et al. Phase I study combining the aurora kinase A inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Invest New Drugs. 2019;37:315–322.
- Graff JN, Higano CS, Hahn NM, et al. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors. Cancer. 2016;122:2524–2533.
- Kelly KR, Friedberg JW, Park SI, et al. Phase I study of the investigational Aurora A kinase inhibitor alisertib plus Rituximab or Rituximab/Vincristine in relapsed/refractory aggressive B-cell lymphoma. Clin Cancer Res. 2018;24:6150–6159.
- Fathi AT, Wander SA, Blonquist TM, et al. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017;102:719–727.
- DuBois SG, Mosse YP, Fox E, et al. Phase II trial of Alisertib in combination with Irinotecan and Temozolomide for patients with relapsed or refractory neuroblastoma. Clin Cancer Res. 2018;24:6142–6149.
- Brunner AM, Blonquist TM, DeAngelo DJ, et al. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020;7:e122–e133.
- Ionkina AA, Tentler JJ, Kim J, et al. Efficacy and molecular mechanisms of differentiated response to the Aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical models of p53-mutated triple-negative breast cancer. Front Oncol. 2017;7:94.
- Chiba Y, Sato S, Itamochi H, et al. Inhibition of Aurora kinase A synergistically enhances cytotoxicity in ovarian clear cell carcinoma cell lines induced by cisplatin: a potential treatment strategy. Int J Gynecol Cancer. 2017;27:1666–1674.
- Lheureux S, Tinker A, Clarke B, et al. A clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the Princess Margaret phase II consortium. Clin Cancer Res. 2018;24:6168–6174.
- Diamond JR, Eckhardt SG, Pitts TM, et al. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018;20:82.
- Petersen W, Liu J, Yuan L, et al. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. Cancer Lett. 2014;354:68–76.
- Moreno L, Marshall LV, Pearson AD, et al. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015;21:267–273.
- Foran J, Ravandi F, Wierda W, et al. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014;14:223–230.
- Duong JK, Griffin MJ, Hargrave D, et al. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. Br J Clin Pharmacol. 2017;83:1713–1722.
- Hay AE, Murugesan A, DiPasquale AM, et al. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk Lymphoma. 2016;57:1463–1466.
- Vormoor B, Veal GJ, Griffin MJ, et al. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatr Blood Cancer. 2017;64:e26351.
- Borges KS, Andrade AF, Silveira VS, et al. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line. Anticancer Drugs. 2017;28:634–644.
- Paller CJ, Wissing MD, Mendonca J, et al. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med. 2014;3:1322–1335.
- Carducci M, Shaheen M, Markman B, et al. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 2018;36:1060–1071.
- Kantarjian HM, Schuster MW, Jain N, et al. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017;92:660–667.
- Chinn DC, Holland WS, Mack PC. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol. 2014;140:1137–1149.
- Amin M, Minton SE, LoRusso PM, et al. A phase I study of MK-5108, an oral Aurora A kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs. 2016;34:84–95.
- Liu Y, Yang EJ, Zhang B, et al. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Lett. 2018;436:28–37.
- Garcia-Manero G, Tibes R, Kadia T, et al. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015;33:870–880.
- Maitland ML, Piha-Paul S, Falchook G, et al. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018;118:1042–1050.
- Zhou Y, Shan S, Li ZB, et al. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci. 2017;108:469–477.
- Deng M, Shi Y, Chen K, et al. CS2164 exerts an antitumor effect against human Non-Hodgkin’s lymphomas in vitro and in vivo. Exp Cell Res. 2018;369:356–362.
- Zhou Y, Fu C, Kong Y, et al. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models. Anticancer Drugs. 2019;30:909–916.
- Sun Y, Yang L, Hao X, et al. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. J Hematol Oncol. 2019;12:9.
- Du J, Yan L, Torres R, et al. Aurora A-selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells, and shows potent preclinical antitumor efficacy. Mol Cancer Ther. 2019;18:2207–2219.
- Amgen Inc. Arylaminophthalazine derivatives as Aurora kinase modulators and their preparation. US20140336182A1; 2014
- Amgen Inc. Preparation of crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts for the treatment of cancer. WO2015084649A1; 2015
- Amgen Inc. Preparation of substituted phthalazinamines as Aurora kinase modulators. WO07087276A1; 2007
- Boehringer Ingelheim International GMBH. Preparation of indolinone derivatives as dual Aurora kinase/MEK inhibitors for treatment of cancer. WO2014009319A1; 2014
- Boehringer Ingelheim International GMBH. New compounds. WO2010012747A1; 2010
- Boehringer Ingelheim International GMBH. Anticancer therapy with dual aurora kinase/MEK inhibitors. WO2012095505A1; 2012
- Boehringer Ingelheim International GMBH. Crystalline form and preparation of indolinone derivative useful as a dual Aurora kinase/MEK inhibitor for treatment of cancer. WO2014009318A1; 2014
- Beijing Xinkaiyuan Pharmaceutical Technology Co., Ltd. Preparation method of Aurora A kinase inhibitor, pharmaceutical composition comprising the same, and application thereof in treating tumors. CN111039940A; 2020
- Curtin University of Technology. Complexes and uses thereof. WO2018170553A1; 2018
- Calitor Sciences, LLC, and Sunshine Lake Pharma Co., Ltd. Preparation of pyrimidinediamine derivatives for use as protein kinase modulators. WO2015148867A1; 2015
- Sunshine Lake Pharma Co., Ltd, and Calitor Sciences, LLC. Preparation of substituted heteroaryl compounds and methods of use in the treatment of protein kinase-mediated disease. WO2017044434A1; 2017
- Sunshine Lake Pharma Co., Ltd, and Calitor Sciences, LLC. Preparation of substituted heteroaryl compounds and methods of use for treatment of protein kinase-mediated disease. WO2017048675A1; 2017.
- Sunshine Lake Pharma Co., Ltd, and Calitor Sciences, LLC. Preparation of substituted heteroaryl compounds, especially pyrimidine-2,4-diamines, and methods of use in the treatment of protein kinase-mediated diseases. WO2019099311A1; 2019
- Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound and its preparation method and application. CN105461694A; 2016
- Sunshine Lake Pharma Co., Ltd and Jiatuo Sciences Company. Substituted heteroaryl compounds as JAK kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. CN108570048A; 2018
- Sunshine Lake Pharma Co., Ltd. Preparation of quinazoline derivatives as Aurora kinase inhibitors. CN104098551A; 2014
- Sunshine Lake Pharma Co., Ltd. Substituted pyrazole-type deriv. as aurora kinase inhibitor useful in treatment of various diseases and its preparation. CN104211692A; 2014
- Sunshine Lake Pharma Co., Ltd. Preparation of pyrazole derivatives as protein kinase over expression inhibitors. CN104447701A; 2015
- Sunshine Lake Pharma Co., Ltd, and Dongguan HEC Pharmaceutical Research and Development Co., Ltd. Pyrazole derivative useful in treatment of proliferative diseases and its preparation. CN105801563A; 2016
- Dalian Medical University. Pyrimidine compounds, their synthetic method and application. CN104693188A; 2015
- Dalian Medical University. Piperazine-pyrimidine-pyrazole compounds as Aurora kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of leukemia. CN104693189A; 2015
- Daegu-Gyeongbuk Medical Innovation Foundation, National Cancer Center, Samsung Life Public Welfare Foundation. Preparation of pyrrolopyrimidine derivatives for preventing or treating protein kinase-related disease. WO2018155916A2; 2018
- East China Normal University. Method for preparing 3,3-spiro(2-tetrahydrofuran)oxindole polycyclic compound and application. CN103554120A; 2014
- East China Normal University. 3,3-Spiro(2-tetrahydrofuran)oxindole polycyclic derivatives, preparation method and application. CN103554121A; 2014
- Jacobio Pharmaceuticals Co., Ltd. Novel pyrimidine derivatives useful as FAK/aurora kinase inhibitors and their preparation. WO2018019252A1; 2018
- Lanzhou University. Aurora kinase A inhibitor, its preparation and application. CN106674197A; 2017
- Sang CY, Qin WW, Zhang XJ, et al. Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors. Bioorg Med Chem. 2019;27:65–78.
- Lanzhou University. 3,5-disubstituted 2-amino-pyrazine compound for anticancer drug and its preparation method. CN108250191A; 2018
- Bo YX, Xiang R, Xu Y, et al. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors. Bioorg Med Chem. 2020;28:115351.
- Lanzhou University. Preparation of piperazinone compounds for treating cancer. CN108250150A; 2018
- Wang W, Feng X, Liu HX, et al. Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors. Bioorg Med Chem. 2018;26:3217–3226.
- Zhang XJ, Xu Y, Mou HX, et al. The synthesis and antitumor properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors. Bioorg Med Chem Lett. 2020;30:127556.
- City of Hope, National and Kapodistrian University of Athens. Preparation of 5-bromoindirubin derivatives for the treatment of cancer. WO2014153023A1; 2014
- Nanjing University. An AURKB small molecule inhibitor and application. WO2018086584A1; 2018
- Nanjing University. An AURKB small molecule inhibitor and application. CN106565587A; 2017
- Regents of The University of Minnesota. Preparation of isatin derivatives as Aurora kinase inhibitors. WO2014066840A1; 2014
- The University of California. Aurora kinase inhibitors. WO2014190207A1; 2014
- TransTech Pharma, LLC. Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors. WO2014193696A2; 2014
- Sun Yat-Sen University. Substituted quinazolines derivative as Aurora kinase inhibitor and its preparation. CN105503837A; 2016
- Sun Yat-Sen University. Preparing method and application of quinazoline derivative capable of selectively inhibiting Aurora A. CN106957303A; 2017
- Long L, Wang YH, Zhuo JX, et al. Structure-based drug design: synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors. Eur J Med Chem. 2018;157:1361–1375.
- Vertex Pharmaceuticals Incorporated. Preparation of aminopyrimidines as Aurora protein kinase inhibitors. US20140303137; 2014
- Nektar Therapeutics Al. Oligomer-diarylpiperazine conjugates as opioid receptor inhibitors and their preparation. WO2009094209A1; 2009
- Xuzhou Medical University. 3-(4-Phenyl-1H-2-imidazolyl)-1H-pyrazole compound useful in treatment of cancer and its preparation. CN111004220A; 2020
- Zhao QC, Fan Y, Zhou Z Phenolic acid concentrated ingredients of Eriocaulon buergerianum and application in preparing antitumor drugs. CN106467564A; 2017
- Zhao QC, Fan YH, Xu YN, et al. Process for preparation of chalcone flavonoid derivatives as aurora kinase inhibitor and. CN106543155A; 2017
- Eli Lilly and Company. Preparation of aminopyridine compounds as Aurora A kinase inhibitors. WO2016077161A1; 2016
- Nankai University. Aurora kinase-B antagonist and its application in preparation of drug for treatment or prevention of disease caused by high expression or high activity of aurora kinase-B. CN110483463A; 2019
- Shenzhen Institutes of Advanced Technology. Aurora A protein inhibitor, its preparation method and medicinal application. CN109970720A; 2019
- Third Affiliated Hospital of Sun Yat-sen University. Pyrimidine derivative capable of reversing drug resistance of tumor cell, and its application as AURKA kinase inhibitor for treating relapsed leukemia. CN108276390A; 2018
- Long L, Luo Y, Hou ZJ, et al. Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold. Eur J Med Chem. 2018;145:805–812.
- Nemucore Medical Innovations, Inc., USA. Degradation of Aurora kinase (AURK) by conjugation of AURK inhibitors with e3 ligase ligand. WO2020223456A1; 2020.
- Sun Yat-sen University Cancer Center Affiliated Tumor Hospital of Sun Yat-sen University. Preparation of pyrimidine derivatives with aurora kinase degradation and antitumor agents. CN112062768A; 2020
- Adhikari B, Bozilovic J, Diebold M, et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat Chem Biol. 2020;16:1179–1188.
- Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol. 2008;610:54–73.
- Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC 1/2 inhibitors and selective inhibitors of aurora A kinase for treatment of proliferative disorders such as cancer. WO2014153509A1; 2014
- Clovis Oncology, Inc. Therapeutic combinations for treating cancer comprising an irreversible mutant EGFR inhibitor and an antineoplastic agent such as an Aurora kinase inhibitor. WO2015112705A2; 2015
- Millennium Pharmaceuticals, Inc. Combination of phosphatidylinositol-3-kinase (PI3K) inhibitors and aurora kinase inhibitors for treatment of cancer. WO2017015437A2; 2017
- Millennnium Pharmaceuticals, Inc. Combination of Raf kinase inhibitors and aurora kinase inhibitors for treating cancer. WO2016106357A1; 2016
- Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof. WO2018081585A1; 2018
- Millennium Pharmaceuticals, Inc. Administration of Aurora kinase inhibitor and chemotherapeutic agents. WO2017015316A1; 2017
- Guangzhou Virotech Pharmaceutical Co., Ltd. Use of aurora kinase inhibitor and alphavirus in preparing anti-tumor drug. WO2019129234A1; 2019
- AstraZeneca AB. Combination therapy using AZD2811 and 5-azacytidine for treating hematological cancer. WO2020026102A1; 2020
- AstraZeneca AB. Combination of AZD2811 and venetoclax for treating cancer. WO2020026100A1; 2020
- Tsinghua University. Composition containing Aurora kinase inhibitor and immune checkpoint inhibitor for treating breast cancer and application thereof in treatment of breast cancer (triple negative breast cancer) . CN109675040A; 2019
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research